TSC1 and cystic kidney disease: Targeting PRAS40 directly or suppressing PRAS40 expression indirectly through enhancement of miR-142-3p impairs the formation of TSC-associated renal cysts, which may provide promising therapeutic approaches for diseases with hyperactivated mTOR signaling.